GlassScriptPhysician profile
Edward James Lane
NPI 1881700342
$1,469.24
in general payments reported to CMS, 2019-2025
26 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $59.75 · 2022: $38.69 · 2023: $322 · 2024: $465 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $149.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $139.18 | 2023-2025 | |
| Pfizer INC. | $123.07 | 2023-2024 | |
| Abbott Laboratories | $114.63 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $106.79 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $99.52 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $84.42 | 2019-2023 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $74.71 | 2019-2025 | |
| Exact Sciences Corporation | $71.44 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $71.18 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $69.86 | 2020-2024 | Vaxneuvance, Gardasil, Vaxelis |
| Xeris Pharmaceuticals, INC. | $45.50 | 2024-2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $44.66 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.43 | 2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $34.55 | 2019-2024 | Trintellix |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29.68 | 2024-2025 | Airsupra, Farxiga |
| Actelion Pharmaceuticals US, INC. | $28.29 | 2025 | Opsumit, Uptravi |
| Otsuka America Pharmaceutical, INC. | $24.31 | 2025 | Rexulti |
| Nevro Corp. | $20.15 | 2022 | |
| Shield Therapeutics INC | $18.84 | 2024 | |
| Axsome Therapeutics, INC. | $17.59 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.22 | 2025 | Xifaxan |
| Amgen INC. | $13.75 | 2024 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $13.54 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.93 | 2019 | |
| Allergan, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.